Rein Therapeutics Q1'26 Revenue Estimate Set at $0, EPS Expected at ($0.49)
RNTX is trading near its 52-week low of $1 (13% above the low).
Summary
Rein Therapeutics is expected to report Q1'26 revenue of $0 and an EPS loss of ($0.49) when it announces results on May 20. For a clinical-stage biotechnology company, a $0 revenue estimate is typical as it indicates the absence of commercialized products. This financial estimate provides an update on the company's expected performance following recent positive Phase 2 clinical trial progress and a significant $50 million dilutive public offering earlier this month. Traders will be watching the actual earnings release for any deviations from these estimates and further updates on its clinical pipeline.
At the time of this announcement, RNTX was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.4M. The 52-week trading range was $1.00 to $2.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.